All In Biotech

Drug Trial Radar · NCT06290375

A Study of HSK21542 in a Peritoneal Dialysis Pruritus Population.

A Multi-center Stage II Trial to Evaluate the Efficacy, Safety, and Pharmacokinetic Profile of HSK21542 Tablets for the Treatment of Moderate-to-severe Pruritus in Peritoneal Dialysis Subjects

Last checked: Nov 20, 2026Latest source record: Mar 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 250 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

250

Planned (sponsor's estimate)

Start

Mar 8, 2024

Primary completion

Mar 8, 2024

Study completion Apr 11, 2025

Sponsor

Sponsor type
Industry
First posted
Mar 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a two- stage study. Stage I is a multicenter, open-label trial;Stage II was a multi-center, randomized, double-blind, placebo-controlled trial. About 250 maintenance peritoneal dialysis patients with moderate or above pruritus are planned to be enrolled.

Conditions

  • Pruritus

Interventions

  • HSK21542 tabletDrug

    once-daily

  • PlaceboDrug

    once-daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects with an improvement of ≥ 4points from baseline in the weekly average of the daily Worst Itch Numeric Rating Scale (WI-NRS) after 12 weeks of treatment.Time frame: Week 12

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.